Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG031
MIFTS: 56

Lung Benign Neoplasm

Categories: Cancer diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lung Benign Neoplasm

About this section

MalaCards integrated aliases for Lung Benign Neoplasm:

Name: Lung Benign Neoplasm 12 15
Lung Neoplasms 45 74
Tumor of the Lung 12
Lung Tumor 56

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3683
MeSH 45 D008175
NCIt 51 C3200
UMLS 74 C0024121
Sources

Summaries for Lung Benign Neoplasm

About this section
MalaCards based summary : Lung Benign Neoplasm, also known as lung neoplasms, is related to carcinoid syndrome and pulmonary blastoma, and has symptoms including hemoptysis An important gene associated with Lung Benign Neoplasm is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Terbutaline and Ipratropium have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Lung Benign Neoplasm

About this section

Diseases related to Lung Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 413)
# Related Disease Score Top Affiliating Genes
1 carcinoid syndrome 30.9 CHGA ENO2 SYP
2 pulmonary blastoma 30.3 CHGA EGFR KRAS NKX2-1 SYP TP53
3 glomus tumor 30.2 ENO2 SYP TP53
4 interstitial lung disease 30.0 EGFR NKX2-1 SFTPB
5 mucoepidermoid carcinoma 29.9 CHGA EGFR KRT7
6 paraganglioma 29.9 CHGA ENO2 SYP
7 alveoli adenoma 29.9 KRAS KRT7 NKX2-1
8 cystadenoma 29.9 CHGA KRT7 SYP
9 rhabdoid cancer 29.8 ENO2 SYP TP53
10 pulmonary sclerosing hemangioma 29.6 CHGA KRT7 NKX2-1 SFTPB SYP
11 sclerosing hemangioma 29.6 CHGA KRT7 NKX2-1 SFTPB SYP
12 sarcoma 29.6 HRAS KRAS RAF1 TP53
13 adenocarcinoma 29.6 EGFR HRAS KRAS RAF1 TP53
14 myeloma, multiple 29.5 HRAS KRAS NCAM1 TP53
15 pleomorphic carcinoma 29.5 EGFR KRT7 NKX2-1 TP53
16 mucinous adenocarcinoma 29.5 EGFR KRAS KRT7 NKX2-1
17 ganglioglioma 29.5 CHGA ENO2 SYP TP53
18 thymoma 29.5 EGFR HRAS NKX2-1 TP53
19 basaloid squamous cell carcinoma 29.4 EGFR ENO2 KRT7 SYP TP53
20 malignant pheochromocytoma 29.4 CHGA ENO2 SYP
21 hemangioma 29.4 CHGA ENO2 KRAS NKX2-1 SFTPB SYP
22 lung disease 29.3 EGFR GRP NKX2-1 SFTPB
23 renal cell carcinoma, nonpapillary 29.3 EGFR FHIT KRT7 NKX2-1
24 nasopharyngeal carcinoma 29.3 CADM1 EGFR HRAS TP53
25 squamous cell carcinoma, head and neck 29.2 EGFR FHIT HRAS TP53
26 esophageal cancer 29.2 EGFR FHIT HRAS KRAS TP53
27 thyroid cancer 29.1 CHGA EGFR HRAS KRAS NKX2-1 TP53
28 bronchiolo-alveolar adenocarcinoma 29.1 EGFR FHIT KRAS KRT7 NKX2-1
29 neuroendocrine tumor 29.0 CHGA ENO2 GRP KRT7 NCAM1 NKX2-1
30 gastrointestinal stromal tumor 28.9 CHGA EGFR ENO2 KRAS NCAM1 SYP
31 small cell carcinoma 28.9 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
32 large cell neuroendocrine carcinoma 28.9 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
33 ewing sarcoma 28.8 CHGA EGFR ENO2 NCAM1 SYP TP53
34 pheochromocytoma 28.7 CHGA ENO2 NCAM1 RAF1 SYP
35 small cell cancer of the lung 28.4 CHGA EGFR ENO2 GRP KRT7 NCAM1
36 lung cancer susceptibility 3 27.8 CADM1 EGFR FHIT HRAS KRAS KRT7
37 lung cancer 25.6 CADM1 CHGA EGFR ENO2 FHIT GRP
38 hilar lung neoplasm 12.1
39 bronchiectasis 11.2
40 lung leiomyoma 11.1
41 lung adenoma 11.1
42 rhabdomyosarcoma 2 10.9
43 pleuropulmonary blastoma 10.9
44 ovarian germ cell cancer 10.5 KRT7 NKX2-1
45 solid adenocarcinoma with mucin production 10.5 KRT7 NKX2-1
46 papillary adenoma 10.5 KRT7 NKX2-1
47 colloid adenoma 10.5 NKX2-1 TP53
48 duodenum adenocarcinoma 10.5 KRAS KRT7
49 ovarian germ cell teratoma 10.5 KRT7 NKX2-1
50 lung acinar adenocarcinoma 10.5 KRT7 NKX2-1

Graphical network of the top 20 diseases related to Lung Benign Neoplasm:



Diseases related to Lung Benign Neoplasm
Sources

Symptoms & Phenotypes for Lung Benign Neoplasm

About this section

UMLS symptoms related to Lung Benign Neoplasm:


hemoptysis

GenomeRNAi Phenotypes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.91 EGFR HRAS KRAS NCAM1
2 Decreased viability GR00106-A-0 9.91 KRAS
3 Decreased viability GR00221-A-1 9.91 EGFR HRAS KRAS
4 Decreased viability GR00221-A-2 9.91 HRAS KRAS
5 Decreased viability GR00221-A-3 9.91 HRAS
6 Decreased viability GR00221-A-4 9.91 EGFR
7 Decreased viability GR00301-A 9.91 KRAS
8 Decreased viability GR00381-A-1 9.91 KRAS
9 Decreased viability GR00402-S-2 9.91 EGFR HRAS KRAS NCAM1
10 Increased cell migration GR00055-A-3 8.92 EGFR HRAS KRAS NCAM1

MGI Mouse Phenotypes related to Lung Benign Neoplasm:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 CADM1 ENO2 GRP HRAS KRAS NCAM1
2 homeostasis/metabolism MP:0005376 10.11 CHGA EGFR FHIT HRAS KRAS KRT7
3 nervous system MP:0003631 10.03 CADM1 CHGA EGFR ENO2 GRP HRAS
4 endocrine/exocrine gland MP:0005379 10.01 CADM1 CHGA EGFR HRAS KRAS NKX2-1
5 craniofacial MP:0005382 9.91 EGFR ENO2 HRAS KRAS RAF1 TP53
6 neoplasm MP:0002006 9.87 EGFR FHIT HRAS KRAS NKX2-1 RAF1
7 no phenotypic analysis MP:0003012 9.7 CHGA EGFR HRAS KRAS NKX2-1 RAF1
8 normal MP:0002873 9.56 CADM1 EGFR HRAS KRAS NKX2-1 RAF1
9 respiratory system MP:0005388 9.23 EGFR ENO2 HRAS KRAS NKX2-1 RAF1
Sources

Drugs & Therapeutics for Lung Benign Neoplasm

About this section

Drugs for Lung Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1058)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Terbutaline Approved Phase 4 23031-25-6 5403
2
Ipratropium Approved Phase 4,Not Applicable 60205-81-4, 22254-24-6 43232 657309
3
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 63006 5281004
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
5
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 150399-23-8, 137281-23-3 60843 446556
6
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 6006 143
7
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 441203 84093 2767
8
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
9
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
10
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
11
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
12
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
13
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 114977-28-5 148124
14
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
15
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
16
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
17
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
18
Midazolam Approved, Illicit Phase 4,Phase 1,Not Applicable 59467-70-8 4192
19
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
22
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
23
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6
24
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
25
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71486-22-1 60780 44424639
26
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
27
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
28
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 159351-69-6 6442177 70789204
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
30
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53123-88-9 46835353 6436030 5284616
31
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
32
afatinib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 850140-72-6, 439081-18-2 10184653
33
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
34
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 2078-54-8 4943
35
Nedaplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95734-82-0
36
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
37
Ropivacaine Approved Phase 4,Phase 2,Not Applicable 84057-95-4 71273 175805
38
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
39
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
40
Amifostine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20537-88-6 2141
41
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-11-5 942 89594
42
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable 616-91-1 12035
43
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
44
Pembrolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1374853-91-4
45
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
46
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
47
Atezolizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1380723-44-3
48
Sufentanil Approved, Investigational Phase 4,Not Applicable 56030-54-7 41693
49
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 151165 6918365
50
Ondansetron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595

Interventional clinical trials:

(show top 50) (show all 7280)
# Name Status NCT ID Phase Drugs
1 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
2 Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
3 Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
4 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
5 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
6 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
7 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
8 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
9 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
10 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
11 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
12 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
13 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
14 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Unknown status NCT02275702 Phase 4 Dexamethasone IV;Saline solution
15 Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
16 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
17 First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Unknown status NCT01646450 Phase 4 Icotinib
18 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
19 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
20 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
21 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
22 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
23 Effects of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction in Patients With Lung Cancer Completed NCT03393949 Phase 4 Methylprednisolone 1 mg•kg-1;Methylprednisolone 0.5mg•kg-1
24 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
25 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
26 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
27 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
28 Fentanyl Matrix in Lung Cancer Pain Completed NCT01060137 Phase 4 fentanyl matrix
29 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
30 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed NCT00770588 Phase 4 Gefitinib;Placebo
31 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
32 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4 erlotinib [Tarceva]
33 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage â…¢A NSCLC Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
34 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4 zoledronic acid
35 Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
36 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4 Erlotinib
37 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
38 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
39 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
40 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00949910 Phase 4 Erlotinib
41 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
42 Cryotherapy Combine Icotinib for Advanced NSCLC Treatment Completed NCT02744664 Phase 4 Icotinib
43 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
44 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
45 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
46 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
47 Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Completed NCT03092986 Phase 4 Paclitaxel;Carboplatin;Cisplatin;Vinblastine Sulfate
48 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
49 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Completed NCT02208843 Phase 4 Afatinib
50 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine

Search NIH Clinical Center for Lung Benign Neoplasm

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: lung neoplasms

Sources

Genetic Tests for Lung Benign Neoplasm

About this section
Sources

Anatomical Context for Lung Benign Neoplasm

About this section

MalaCards organs/tissues related to Lung Benign Neoplasm:

42
Lung, Brain, Breast, Testes, T Cells, Bone, Prostate
Sources

Publications for Lung Benign Neoplasm

About this section

Articles related to Lung Benign Neoplasm:

(show top 50) (show all 85)
# Title Authors Year
1
Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. ( 29360191 )
2018
2
Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. ( 30154579 )
2018
3
Lung Neoplasms with Low F18-Fluorodeoxyglucose Avidity. ( 29157381 )
2018
4
CT-guided percutaneous radiofrequency ablation for lung neoplasms adjacent to the pericardium. ( 30032841 )
2018
5
Microwave Ablation for Lung Neoplasms: A Retrospective Analysis of Long-Term Results. ( 27993505 )
2017
6
Epigenome-wide association study of smoking and DNA methylation in non-small cell lung neoplasms. ( 27602958 )
2016
7
Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. ( 26374070 )
2015
8
Utility of telepathology as a consultation tool between an off-site surgical pathology suite and affiliated hospitals in the frozen section diagnosis of lung neoplasms. ( 26605120 )
2015
9
Mutation spectra of Kras and Tp53 in urethral and lung neoplasms in B6C3F1 mice treated with 3,3',4,4'-tetrachloroazobenzene. ( 23703846 )
2014
10
Differentiation of lung neoplasms with lepidic growth and good prognosis from those with poor prognosis using computer-aided 3D volumetric CT analysis and FDG-PET. ( 24003260 )
2014
11
Higher susceptibility of spontaneous and NNK-induced lung neoplasms in connexin 43 deficient CD1 × AJ F1 mice: paradoxical expression of connexin 43 during lung carcinogenesis. ( 22344786 )
2013
12
Growth pattern analysis of murine lung neoplasms by advanced semi-automated quantification of micro-CT images. ( 24376755 )
2013
13
Low-sensitivity FDG-PET studies: less common lung neoplasms. ( 22681674 )
2012
14
Difference in clonality as a tool for differential diagnosis of primary versus secondary lung neoplasms. ( 22722795 )
2012
15
Use of endobronchial valves for the treatment of bronchopleural fistulas after thermal ablation of lung neoplasms. ( 22920983 )
2012
16
Gene therapy for lung neoplasms. ( 22054892 )
2011
17
The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study. ( 20961771 )
2011
18
Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid or neuroendocrine morphology. ( 21319315 )
2011
19
GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. ( 19620839 )
2009
20
Risk factors involved in the development of pneumothorax during radiofrequency ablation of lung neoplasms. ( 19542382 )
2009
21
Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. ( 19161739 )
2009
22
Research reporting standards for percutaneous thermal ablation of lung neoplasms. ( 19246213 )
2009
23
Tumour characteristics and therapeutic results after percutaneous radiofrequency ablation of secondary lung neoplasms. ( 19531455 )
2009
24
Incidence and outcomes of malignant pediatric lung neoplasms. ( 19631347 )
2009
25
Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. ( 18413732 )
2008
26
Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from B6C3F1 mice exposed to cumene. ( 18648094 )
2008
27
Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT. ( 16395694 )
2007
28
Risk factors for occurrence of local tumor progression after percutaneous radiofrequency ablation for lung neoplasms. ( 18092293 )
2007
29
Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. ( 16506596 )
2006
30
Pneumothorax as a complication of percutaneous radiofrequency ablation for lung neoplasms. ( 17057004 )
2006
31
Approach to the diagnosis of neuroendocrine lung neoplasms: variabilities and pitfalls. ( 17185177 )
2006
32
Predominant K-ras codon 12 G --> A transition in chemically induced lung neoplasms in B6C3F1 mice. ( 14713543 )
2004
33
Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. ( 15126656 )
2004
34
The significance of associated pre-invasive lesions in patients resected for primary lung neoplasms. ( 15200997 )
2004
35
Radiofrequency ablation of 40 lung neoplasms: preliminary results. ( 15269026 )
2004
36
Radiofrequency thermal ablation of 69 lung neoplasms. ( 15675488 )
2004
37
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors]. ( 12652739 )
2003
38
A review of intractable facial pain secondary to underlying lung neoplasms. ( 12534572 )
2003
39
CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern. ( 12591704 )
2003
40
Increased incidence of lung neoplasms among HIV-infected men and the need for improved prevention. ( 14526218 )
2003
41
Gene therapy for lung neoplasms. ( 11901916 )
2002
42
Percutaneous radiofrequency ablation of lung neoplasms: a minimally invasive strategy for inoperable patients. ( 12229953 )
2002
43
Unusual primary lung neoplasms. ( 11470980 )
2001
44
Pulmonary complications in patients with head and neck and lung neoplasms. ( 10722023 )
2000
45
Glucose transporter expression in developing fetal lungs and lung neoplasms. ( 10425560 )
1999
46
Tumor markers kinetic in malignant lung neoplasms. ( 10350122 )
1999
47
K-ras mutations in 239PuO2 canine lung neoplasms. ( 10397446 )
1998
48
Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. ( 9158711 )
1997
49
Cytometry with DAPI-stained tumor imprints. A reliable tool for improved intraoperative analysis of lung neoplasms. ( 8744500 )
1996
50
Bronchoscopic, photodynamic, and laser diagnosis and therapy of lung neoplasms. ( 9363151 )
1996
Sources

Variations for Lung Benign Neoplasm

About this section
Sources

Expression for Lung Benign Neoplasm

About this section
Search GEO for disease gene expression data for Lung Benign Neoplasm.
Sources

Pathways for Lung Benign Neoplasm

About this section

Pathways related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 38
Show member pathways
 12.95 EGFR HRAS KRAS RAF1 TP53
2
Endometrial cancer 38
Show member pathways
 12.84 EGFR HRAS KRAS RAF1 TP53
3
Pathways in cancer 38
12.81 EGFR HRAS KRAS RAF1 TP53
4
MAPK signaling pathway 1 38
12.74 EGFR HRAS KRAS RAF1 TP53
5
Gastric cancer 38
Show member pathways
 12.73 EGFR HRAS KRAS RAF1 TP53
6
4-1BB Pathway 65
Show member pathways
 12.65 EGFR HRAS KRAS RAF1 TP53
7
Immune response IL-23 signaling pathway 23
Show member pathways
 12.56 EGFR HRAS KRAS TP53
8
Neuroscience 4
12.56 ENO2 NCAM1 NKX2-1 SYP
9
Glioma 38
Show member pathways
 12.55 EGFR FHIT HRAS KRAS RAF1 TP53
10
ErbB signaling pathway 1 38
Show member pathways
 12.51 EGFR HRAS KRAS RAF1 TP53
11
MicroRNAs in cancer 38
12.47 EGFR HRAS KRAS RAF1 TP53
12
mTOR signaling pathway (KEGG) 66
Show member pathways
 12.44 EGFR HRAS KRAS RAF1 TP53
13
Apoptosis Pathway 73
Show member pathways
 12.42 EGFR HRAS KRAS TP53
14
VEGF Pathway (Qiagen) 65
Show member pathways
 12.38 EGFR HRAS KRAS RAF1
15
Phospholipase D signaling pathway 38
Show member pathways
 12.38 EGFR HRAS KRAS RAF1
16
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.37 EGFR HRAS KRAS RAF1
17
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.23 HRAS KRAS RAF1 TP53
18
VEGF Signaling Pathway 62 68
Show member pathways
 12.21 EGFR HRAS KRAS RAF1
19
EGF/EGFR Signaling Pathway 1
12.16 EGFR HRAS KRAS RAF1
20
Proteoglycans in cancer 38
12.16 EGFR HRAS KRAS RAF1 TP53
21
Cellular senescence (KEGG) 38
12.14 HRAS KRAS RAF1 TP53
22
mTOR Pathway 73
Show member pathways
 12.14 HRAS KRAS RAF1 TP53
23
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.12 EGFR HRAS KRAS RAF1 TP53
24
NGF Pathway 65
Show member pathways
 12.11 HRAS KRAS RAF1 TP53
25
Development EGFR signaling via small GTPases 23
Show member pathways
 12.1 EGFR HRAS KRAS RAF1
26
FoxO signaling pathway 38
Show member pathways
 12.05 EGFR HRAS KRAS RAF1
27
UVA-Induced MAPK Signaling 65
Show member pathways
 12.02 EGFR HRAS KRAS TP53
28
MAPK Pathway 73
Show member pathways
 12 EGFR RAF1 TP53
29
Sphingolipid signaling pathway 38
11.97 HRAS KRAS RAF1 TP53
30
DNA Damage Response (only ATM dependent) 1
11.96 HRAS KRAS TP53
31
Serotonergic synapse 38
11.96 HRAS KRAS RAF1
32
AKT Signaling Pathway 68
11.96 EGFR HRAS KRAS RAF1 TP53
33
Thyroid hormone signaling pathway 38
11.95 HRAS KRAS RAF1 TP53
34
MAP Kinase Signaling 4
11.94 HRAS KRAS RAF1
35
Signaling by ERBB4 67
Show member pathways
 11.92 EGFR HRAS KRAS
36
Senescence and Autophagy in Cancer 1
11.91 HRAS RAF1 TP53
37
Jak-Stat Signaling Pathway (sino) 68
11.85 EGFR HRAS KRAS RAF1
38
VEGF Pathway (Tocris) 73
Show member pathways
 11.79 HRAS KRAS RAF1
39
G-protein signaling_RhoA regulation pathway 23
11.7 EGFR HRAS KRAS RAF1
40
Glioblastoma Multiforme 65
11.7 EGFR HRAS KRAS RAF1 TP53
41
Pathways Affected in Adenoid Cystic Carcinoma 1
11.68 HRAS RAF1 TP53
42
Mitophagy - animal 38
11.67 HRAS KRAS TP53
43
Negative regulation of MAPK pathway 67
Show member pathways
 11.67 HRAS KRAS RAF1
44
Long-term depression 38
11.62 HRAS KRAS RAF1
45
IL-2 Gene Expression in Activated and Quiescent T-Cells 65
Show member pathways
 11.59 EGFR HRAS RAF1
46
Agrin Interactions at Neuromuscular Junction 65
11.59 EGFR HRAS KRAS
47
DNA damage_Role of Brca1 and Brca2 in DNA repair 23
11.56 HRAS KRAS RAF1 TP53
48
Signal transduction_JNK pathway 23
11.46 HRAS RAF1 TP53
49
G-protein signaling_Cross-talk between Ras-family GTPases 23
11.38 EGFR HRAS KRAS RAF1
50
Aryl Hydrocarbon Receptor 1
11.35 EGFR HRAS KRAS RAF1
Sources

GO Terms for Lung Benign Neoplasm

About this section

Biological processes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.89 CADM1 FHIT HRAS RAF1 TP53
2 animal organ morphogenesis GO:0009887 9.7 HRAS NKX2-1 SFTPB
3 Ras protein signal transduction GO:0007265 9.61 HRAS KRAS TP53
4 positive regulation of protein phosphorylation GO:0001934 9.56 EGFR HRAS KRAS RAF1
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.54 HRAS KRAS RAF1
6 epithelial tube branching involved in lung morphogenesis GO:0060441 9.51 KRAS NKX2-1
7 positive regulation of MAP kinase activity GO:0043406 9.5 EGFR HRAS KRAS
8 cerebral cortex cell migration GO:0021795 9.48 EGFR NKX2-1
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.46 EGFR TP53
10 response to isolation stress GO:0035900 9.4 HRAS KRAS
11 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.16 CHGA GRP
12 regulation of long-term neuronal synaptic plasticity GO:0048169 9.13 HRAS KRAS SYP
13 MAPK cascade GO:0000165 9.02 EGFR HRAS KRAS NCAM1 RAF1

Molecular functions related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.02 EGFR FHIT HRAS KRAS RAF1
Sources

Sources for Lung Benign Neoplasm

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....